The PAP does cover Ozempic (same active ingredient, semaglutide) for Type 2 diabetes, but not Wegovy for weight lossand Ozempic is being removed from PAP for Medicare Part D beneficiaries starting January 2026
Key Takeaways for Patients and Clinicians What This Means for Patients on GLP-1 Therapy If you are taking semaglutide, tirzepatide, or similar medications, it's important to maintain perspective
If youre struggling with stubborn areas of fat despite eating well and exercising, it might not be your faultit could be your biology
Hydration: A 2019 research review noted that increased water intake is linked to less fatigue and higher energy levels
one that took 8 years gets a 3-year SPC
Considering these potential side effects, individuals are discouraged from making serious decisions or using social media while receiving ketamine infusions